| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Avenue Therapeutics, Inc.
13D/A
ATXI · 05360L403
|
13.4% |
1/6/2026
Event 1/2/2026
|
||||
|
Mustang Bio, Inc.
13D/A
MBIO · 62818Q302
|
8.0% |
1/5/2026
Event 1/2/2026
|
||||
|
Checkpoint Therapeutics, Inc.
13D/A
CKPT · 162828206
|
0% |
6/3/2025
Event 5/30/2025
|
||||
|
Mustang Bio, Inc.
13D/A
MBIO · 62818Q203
|
12.4% |
1/3/2025
Event 12/31/2024
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.